Literature DB >> 31765477

Erythroid differentiation of myeloblast induced by gilteritinib in relapsed FLT3-ITD-positive acute myeloid leukemia.

Hyun Don Yun1, Sunita Nathan1, Melissa Larson1, Mohammad J Hussain1, Deborah A Katz1, Ankur Varma1, Ira Miller2, Celalettin Ustun1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31765477      PMCID： PMC6880901          DOI： 10.1182/bloodadvances.2019000775

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  16 in total

1.  Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.

Authors:  K C Birendra; Courtney D DiNardo
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-05-05

2.  Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.

Authors:  Amy Sexauer; Alexander Perl; Xiaochuan Yang; Michael Borowitz; Christopher Gocke; Trivikram Rajkhowa; Christian Thiede; Mark Frattini; Grant E Nybakken; Keith Pratz; Judith Karp; B Douglas Smith; Mark Levis
Journal:  Blood       Date:  2012-09-25       Impact factor: 22.113

3.  The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.

Authors:  P D Kottaridis; R E Gale; M E Frew; G Harrison; S E Langabeer; A A Belton; H Walker; K Wheatley; D T Bowen; A K Burnett; A H Goldstone; D C Linch
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

4.  CD71 (transferrin receptor): an effective marker for erythroid precursors in bone marrow biopsy specimens.

Authors:  Derek K Marsee; Geraldine S Pinkus; Hongbo Yu
Journal:  Am J Clin Pathol       Date:  2010-09       Impact factor: 2.493

5.  In vivo evidence for an instructive role of fms-like tyrosine kinase-3 (FLT3) ligand in hematopoietic development.

Authors:  Panagiotis Tsapogas; Lee Kim Swee; Anja Nusser; Natko Nuber; Matthias Kreuzaler; Giuseppina Capoferri; Hannie Rolink; Rhodri Ceredig; Antonius Rolink
Journal:  Haematologica       Date:  2014-01-24       Impact factor: 9.941

6.  Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy.

Authors:  Marta Pratcorona; Salut Brunet; Josep Nomdedéu; Josep Maria Ribera; Mar Tormo; Rafael Duarte; Lourdes Escoda; Ramon Guàrdia; M Paz Queipo de Llano; Olga Salamero; Joan Bargay; Carmen Pedro; Josep Maria Martí; Montserrat Torrebadell; Marina Díaz-Beyá; Mireia Camós; Dolors Colomer; Montserrat Hoyos; Jorge Sierra; Jordi Esteve
Journal:  Blood       Date:  2013-02-01       Impact factor: 22.113

7.  The adhesion molecule E-cadherin and a surface antigen recognized by the antibody 9C4 are selectively expressed on erythroid cells of defined maturational stages.

Authors:  H J Bühring; T Müller; R Herbst; S Cole; I Rappold; W Schuller; X Zhu; U Fritzsch; C Faul; S Armeanu; A Ullrich; G Klein; H Schmidt
Journal:  Leukemia       Date:  1996-01       Impact factor: 11.528

8.  Fms-like tyrosine kinase 3 (Flt3) ligand depletes erythroid island macrophages and blocks medullar erythropoiesis in the mouse.

Authors:  Rebecca N Jacobsen; Bianca Nowlan; Marion E Brunck; Valerie Barbier; Ingrid G Winkler; Jean-Pierre Levesque
Journal:  Exp Hematol       Date:  2015-12-01       Impact factor: 3.084

9.  Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations.

Authors:  Rui Zheng; Alan D Friedman; Donald Small
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

10.  Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.

Authors:  Amir T Fathi; Courtney D DiNardo; Irina Kline; Laurie Kenvin; Ira Gupta; Eyal C Attar; Eytan M Stein; Stephane de Botton
Journal:  JAMA Oncol       Date:  2018-08-01       Impact factor: 33.006
View more
  3 in total

1.  A new FLT3 inhibitor with two cases: the gilteritinib experience.

Authors:  Istemi Serin; Mehmet Hilmi Dogu; Gulben Erdem Huq; Osman Yokus
Journal:  Am J Blood Res       Date:  2021-06-15

2.  Megakaryocytic Expansion in Gilteritinib-Treated Acute Myeloid Leukemia Patients Is Associated With AXL Inhibition.

Authors:  Kran Suknuntha; Yoon Jung Choi; Ho Sun Jung; Aditi Majumder; Sujal Shah; Igor Slukvin; Erik A Ranheim
Journal:  Front Oncol       Date:  2020-12-09       Impact factor: 6.244

3.  Fms-like tyrosine kinase 3 is a regulator of the cardiac side population in mice.

Authors:  Giacomo Della Verde; Michika Mochizuki; Vera Lorenz; Julien Roux; Lifen Xu; Leandra Ramin-Wright; Otmar Pfister; Gabriela M Kuster
Journal:  Life Sci Alliance       Date:  2021-12-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.